CBRT20102 / NRG-BN007 / Andrea Wasilewski
Basic Study Information
Purpose:Location: University of Rochester
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide
to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab
in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation
therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs,
such as temozolomide, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Temozolomide, may not work as well for the treatment of tumors that have the unmethylated
MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors,
such as ipilimumab and nivolumab, may help the body's immune system attack the cancer,
and may interfere with the ability of tumor cells to grow and spread. It is possible
that immune checkpoint inhibitors may work better at time of first diagnosis as opposed
to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may
lengthen the time without brain tumor returning or growing and may extend patients'
life compared to usual treatment with radiation therapy and temozolomide.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search